Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-04-2017 | Retinal Disorders

Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity

Authors: Mirae Kim, Seongyong Jeong, Min Sagong

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 4/2017

Abstract

Purpose

To compare the clinical features and bevacizumab efficacy for macular edema (ME) following branch retinal vein occlusion (BRVO) stratified by baseline visual acuity.

Methods

This retrospective study included a total 117 eyes from 117 consecutive patients with ME following BRVO, who received PRN intravitreal bevacizumab injection and were followed for more than 6 months. The eyes were categorized into three groups according to baseline best-corrected visual acuity (BCVA) (group A, BCVA <20/200; group B, BCVA ≥20/200 and ≤20/40; group C, BCVA >20/40). Baseline demographics, clinical features, BCVA, and central retinal thickness (CRT) at 1, 3, 6, and 12 months after injection and the number of injections were compared.

Results

Groups A–C included 11, 83, and 23 eyes, respectively. The mean baseline CRT was thickest in group A (810.1, 580.8, and 473.5 μm in groups A–C, respectively; p < 0.001) and the percentage of eyes with macular ischemia increased in the worst BCVA group (45.5, 25.0, and 4.3 % in groups A–C, respectively; p = 0.005). The mean BCVA and CRT improved at 1, 3, 6, and 12 months after treatment compared to baseline values in all groups (all, p < 0.001). The number of injections for 6 months was greater in the worst BCVA group (3.2, 2.3, and 1.9 injections in groups A–C, respectively; p = 0.009).

Conclusion

In ME following BRVO, baseline visual acuity correlates with macular ischemia and baseline CRT. Intravitreal bevacizumab treatment results in significant anatomical and functional improvement regardless of baseline visual acuity.

Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247CrossRefPubMed

Klein R, Klein BE, Moss SE, Meuer SM (2000) The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98:133–141PubMedPubMedCentral

Rehak J, Rehak M (2008) Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33:111–131CrossRefPubMedPubMedCentral

Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F (2011) Retinal vein occlusion: current treatment. Ophthalmologica 225:135–143CrossRefPubMed

Kondo M, Kondo N, Ito Y, Kachi S, Kikuchi M, Yasuma TR, Ota I, Miyake K, Terasaki H (2009) Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina 29:1242–1248CrossRefPubMed

Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2004) Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335

Figueroa MS, Contreras I, Noval S, Arruabarrena C (2010) Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 94:1052–1056CrossRefPubMed

Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, Babu RB, Narayana KM (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606, e602CrossRefPubMed

Rabena MD, Pieramici DJ, Castellarin AA, Ma’an AN, Avery RL (2007) Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27:419–425CrossRefPubMed

10.

Gregori NZ, Rattan GH, Rosenfeld PJ, Puliafito CA, Feuer W, Flynn HW Jr, Berrocal AM, Al-Attar L, Dubovy S, Smiddy WE (2009) Safety and efficacy of intravitreal bevacizumab (avastin) for the management of branch and hemiretinal vein occlusion. Retina 29:913–925CrossRefPubMed

11.

Wu L, AREVALO JF, Berrocal MH, Maia M, Roca JA, Morales-Canton V, Alezzandrini AA, Diaz-Llopis MJ (2009) Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina 29:1396–1403CrossRefPubMed

12.

Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U (2008) Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 92:518–522CrossRefPubMed

13.

Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH, Group RVOS (2011) Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 249:183–192CrossRefPubMed

14.

Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ (2008) Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 246:1241–1247CrossRefPubMed

15.

Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG, Investigators B (2010) Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 117:1102–1112, e1101CrossRefPubMed

16.

Thapa R, Maharjan N, Paudyal G (2012) Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results. Clin Ophthalmol (Auckland, NZ) 6:1057–1062CrossRef

17.

Otani T, Kishi S, Maruyama Y (1999) Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 127:688–693CrossRefPubMed

18.

Lin LL, Dong YM, Zong Y, Zheng QS, Fu Y, Yuan YG, Huang X, Qian G, Gao QY (2016) Study of retinal vessel oxygen saturation in ischemic and non-ischemic branch retinal vein occlusion. Int J Ophthalmol 9:99–107PubMedPubMedCentral

19.

Parodi MB, Di Stefano G, Ravalico G (2008) Grid laser treatment for exudative retinal detachment secondary to ischemic branch retinal vein occlusion. Retina 28:97–102CrossRefPubMed

20.

Rehak J, Dusek L, Chrapek O, Fric E, Rehak M (2011) Initial visual acuity is an important prognostic factor in patients with branch retinal vein occlusion. Ophthalmic Res 45:204–209CrossRefPubMed

21.

Yunoki T, Miyakoshi A, Nakamura T, Fujita K, Fuchizawa C, Hayashi A (2012) Treatment of macular edema due to branch retinal vein occlusion with single or multiple intravitreal injections of bevacizumab. Jpn J Ophthalmol 56:159–164CrossRefPubMed

22.

Noma H, Funatsu H, Mimura T, Shimada K (2011) Influence of ischemia on visual function in patients with branch retinal vein occlusion and macular edema. Clin Ophthalmol (Auckland, NZ) 5:679–685CrossRef

23.

Parodi MB, Visintin F, Della Rupe P, Ravalico G (1995) Foveal avascular zone in macular branch retinal vein occlusion. Int Ophthalmol 19:25–28CrossRefPubMed

24.

Murakami T, Tsujikawa A, Miyamoto K, Sakamoto A, Ota M, Ogino K, Yoshimura N (2012) Relationship between perifoveal capillaries and pathomorphology in macular oedema associated with branch retinal vein occlusion. Eye 26:771–780CrossRefPubMedPubMedCentral

25.

Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M, Group SSI (2009) SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 116:504–512CrossRefPubMedPubMedCentral

26.

Siegel RA, Dreznik A, Mimouni K, Bor E, Weinberger D, Bourla DH (2012) Intravitreal bevacizumab treatment for macular edema due to branch retinal vein occlusion in a clinical setting. Curr Eye Res 37:823–829CrossRefPubMed

27.

Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P (2009) One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 247:27–33CrossRefPubMed

28.

Yamada R, Nishida A, Shimozono M, Kameda T, Miyamoto N, Mandai M, Kurimoto Y (2015) Predictive factors for recurrence of macular edema after successful intravitreal bevacizumab therapy in branch retinal vein occlusion. Jpn J Ophthalmol 59:389–393CrossRefPubMed

Title: Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity
Authors: Mirae Kim
Seongyong Jeong
Min Sagong
Publication date: 01-04-2017
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 4/2017
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-016-3535-3

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2017

Effect of corneal collagen crosslinking on subsequent deep anterior lamellar keratoplasty (DALK) in keratoconus

The effect of orbital decompression surgery on interpupillary distance and angle kappa in patients with thyroid-associated orbitopathy

Spectral-domain optical coherence tomography findings in idiopathic lamellar macular hole

Different foveal schisis patterns in each retinal layer in eyes with hereditary juvenile retinoschisis evaluated by en-face optical coherence tomography

Morphological differences between optic disc collaterals and neovascularization on optical coherence tomography angiography

Activated microglia induce the production of reactive oxygen species and promote apoptosis of co-cultured retinal microvascular pericytes